Can Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?

Simply Wall St.07-22

Stoke Therapeutics (STOK) drew investor attention after appointing Thomas McCauley, Ph.D., as Chief Scientific Officer, a move that places an experienced genetic medicines leader at the center of its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653542758?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-22 15:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653542758","market":"sg","top_or_hot":-1,"title":"Can Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?","media":"Simply Wall St.","content":"<div>\n<p>Stoke Therapeutics (STOK) drew investor attention after appointing Thomas McCauley, Ph.D., as Chief Scientific Officer, a move that places an experienced genetic medicines leader at the center of its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/can-stoke-therapeutics-stok-be-a-bargain-as-its-new-cso-resh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-22 15:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/can-stoke-therapeutics-stok-be-a-bargain-as-its-new-cso-resh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stoke Therapeutics (STOK) drew investor attention after appointing Thomas McCauley, Ph.D., as Chief Scientific Officer, a move that places an experienced genetic medicines leader at the center of its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/can-stoke-therapeutics-stok-be-a-bargain-as-its-new-cso-resh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STOK","symbol_name":"Stoke Therapeutics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/can-stoke-therapeutics-stok-be-a-bargain-as-its-new-cso-resh","article_id":"2653542758","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/can-stoke-therapeutics-stok-be-a-bargain-as-its-new-cso-resh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653542758","pubTimestamp":1784705210,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Stoke Therapeutics (STOK) drew investor attention after appointing Thomas McCauley, Ph.D., as Chief Scientific Officer, a move that places an experienced genetic medicines leader at the center of its research and development efforts.\nSee our latest analysis for Stoke Therapeutics.\nStoke Therapeutics shares recently closed at US$28.81, with a 1 day share price return of 4.08% that partially offsets a 30 day share price decline of 7.06%. The 1 year total shareholder return of 112.31% and 3 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"STOK":"Stoke Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"随着 Stoke Therapeutics (STOK) 的新 CSO 重塑故事，它能成为一笔便宜货吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":1.5},"content_text":"Stoke Therapeutics (STOK) drew investor attention after appointing Thomas McCauley, Ph.D., as Chief Scientific Officer, a move that places an experienced genetic medicines leader at the center of its research and development efforts. See our latest analysis for Stoke Therapeutics. Stoke Therapeutics shares recently closed at US$28.81, with a 1 day share price return of 4.08% that partially offsets a 30 day share price decline of 7.06%. The 1 year total shareholder return of 112.31% and 3 year total shareholder return of more than 3x both point to strong longer term momentum around the story. If this kind of genetic medicines story has your attention, it can be useful to see what else is moving in related areas and compare opportunities using our healthcare focused AI stock screener, starting with 39 healthcare AI stocks. After a sharp rerating and with a new Chief Scientific Officer in place, the key issue for Stoke Therapeutics now is whether most of the share price gains already reflect the story or if current pricing still leaves meaningful upside ahead. AdvertisementMost Popular Narrative: 36.1% Undervalued Stoke Therapeutics last closed at $28.81, while the most followed narrative pegs fair value at $45.10, implying a sizeable valuation gap that centers on future Dravet syndrome and optic atrophy opportunities.  The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.  Read the complete narrative. Want to understand why this narrative still lands on a much higher fair value for Stoke Therapeutics? It hinges on aggressive revenue ramps, improving margins, and a rich future earnings multiple that assumes today’s clinical bets pay off. The full story comes from how those pieces fit together, not any single data point. Result: Fair Value of $45.10 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this Stoke Therapeutics narrative depends heavily on the EMPEROR Phase 3 data reading out well and on payers accepting pricing for a high cost rare disease therapy. Find out about the key risks to this Stoke Therapeutics narrative. Next Steps Seeing both optimism and concern around Stoke Therapeutics in this article, it makes sense to review the underlying data yourself and move quickly to build your own view using the 2 key rewards and 1 important warning sign. Looking for more investment ideas beyond Stoke Therapeutics? If Stoke Therapeutics has sharpened your interest, do not stop here. Broaden your watchlist with focused sets of stocks that match specific goals and risk levels.  Target potential growth catalysts early with carefully filtered smaller companies through the 21 elite penny stocks with strong financials. Zero in on quality businesses that may trade below their estimated worth by scanning the 50 high quality undervalued stocks. Prioritize resilience and capital preservation by reviewing companies in the 81 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653542758","isCrawlerRequest":true}